CA2208861A1 - Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of gynaecological disorders - Google Patents

Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of gynaecological disorders

Info

Publication number
CA2208861A1
CA2208861A1 CA002208861A CA2208861A CA2208861A1 CA 2208861 A1 CA2208861 A1 CA 2208861A1 CA 002208861 A CA002208861 A CA 002208861A CA 2208861 A CA2208861 A CA 2208861A CA 2208861 A1 CA2208861 A1 CA 2208861A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
treatment
compound
lower alkoxy
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002208861A
Other languages
English (en)
French (fr)
Inventor
Martin William Edwards
James Robertson Piggott
Virender Mohan Labroo
Ved Prakash Kamboj
Suprabhat Ray
Niels Korsgaard
Michael Shalmi
Birgitte Hjort Guldhammer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2208861A1 publication Critical patent/CA2208861A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002208861A 1995-01-13 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of gynaecological disorders Abandoned CA2208861A1 (en)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
DK4895 1995-01-13
DK0044/95 1995-01-13
DK4495 1995-01-13
DK0047/95 1995-01-13
DK0045/95 1995-01-13
DK4595 1995-01-13
DK4795 1995-01-13
DK4695 1995-01-13
DK0046/95 1995-01-13
DK0048/95 1995-01-13
DK0770/95 1995-06-30
DK77295 1995-06-30
DK77195 1995-06-30
DK77095 1995-06-30
DK0769/95 1995-06-30
DK76895 1995-06-30
DK76995 1995-06-30
DK0768/95 1995-06-30
DK0772/95 1995-06-30
DK0771/95 1995-06-30

Publications (1)

Publication Number Publication Date
CA2208861A1 true CA2208861A1 (en) 1996-07-18

Family

ID=27579214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208861A Abandoned CA2208861A1 (en) 1995-01-13 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of gynaecological disorders

Country Status (11)

Country Link
EP (1) EP0804190A1 (no)
JP (1) JPH10511962A (no)
CN (1) CN1168096A (no)
AU (1) AU693628B2 (no)
CA (1) CA2208861A1 (no)
CZ (1) CZ212297A3 (no)
HU (1) HUP9702244A3 (no)
IL (1) IL116746A0 (no)
MX (1) MX9705219A (no)
NO (1) NO973243D0 (no)
WO (1) WO1996021444A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994390A (en) * 1996-10-28 1999-11-30 Novo Nordisk Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6043269A (en) * 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ATE229519T1 (de) * 1996-10-28 2002-12-15 Novo Nordisk As Neue cis-3,4-chromanderivate zur vorbeugung oder behandlung von oestrogenbezogenen krankheiten oder syndromen
ZA979644B (en) * 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
IL129622A0 (en) * 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU4772097A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6316494B1 (en) 1996-10-28 2001-11-13 Novo Nordisk A/S cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
JP2002503213A (ja) * 1996-10-28 2002-01-29 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患または症候群の防止または治療に有用な新規なｃｉｓ―３，４―クロマン誘導体
JP2001502706A (ja) * 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連病あるいは症候群の予防または治療に有用な新規トランス―３，４クロマン誘導体
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
CA2270055A1 (en) * 1996-10-28 1998-05-07 Novo Nordisk A/S Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU4699897A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (-)-enantiomers of (cis)-3,4-chroman derivatives useful in the preve ntion or treatment of estrogen related diseases or syndromes
AU4772297A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5919817A (en) * 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5958967A (en) * 1996-10-28 1999-09-28 Novo Nordisk A/S Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU2001256164A1 (en) 2000-03-01 2001-09-12 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
US7601855B2 (en) 2004-09-21 2009-10-13 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US9701655B2 (en) 2014-02-07 2017-07-11 Novogen Limited Functionalised benzopyran compounds and use thereof
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
NO973243L (no) 1997-07-11
MX9705219A (es) 1997-10-31
HUP9702244A3 (en) 1999-12-28
AU4329396A (en) 1996-07-31
JPH10511962A (ja) 1998-11-17
AU693628B2 (en) 1998-07-02
NO973243D0 (no) 1997-07-11
CN1168096A (zh) 1997-12-17
IL116746A0 (en) 1996-05-14
CZ212297A3 (en) 1997-11-12
HUP9877967A2 (en) 1998-12-28
WO1996021444A1 (en) 1996-07-18
EP0804190A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
AU693628B2 (en) Use of 3,4-diphenylchromans
US5726202A (en) Benign prostatic hypertrophy
US5883118A (en) Prostatic carcinoma
EP0873120A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5756539A (en) 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
CA2208859A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
US5919812A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia
EP0804187A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
WO1998033499A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
US5780502A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
WO1998002154A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
MXPA97005219A (en) Use of 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment of profilaxis of disorders ginecologi
WO1998033500A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment
WO1998032437A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more psychiatric disorders
KR19980701383A (ko) 부인병 질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia)
EP0921797A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for lowering intraocular pressure
MXPA97005218A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis de ginecomastia idiopatica o fisiologica
KR19980701384A (ko) 측발성 또는 생리적 여성형유방의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20020110